Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (21)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Davies, S. P.
Right arrow Articles by Brown, E. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Davies, S. P.
Right arrow Articles by Brown, E. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (1992) 7: 848-854
© 1992 European Renal Association-European Dialysis and Transplant Association

research-article

Pharmacokinetics of ciprofloxacin and vancomycin in patients with acute renal failure treated by continuous haemodialysis

S. P. Davies, B. S. Azadian, W. J. Kox and E. A. Brown

Charing Cross and Westminster Medical School Charing Cross Hospital London UK

Correspondence and offprint requests to: Correspondence and offprint requests to: Dr S. P. Davies, Department of Medicine, Charing Cross Hospital, Fulham Palace Road, London W6 8RF, UK

To determine appropriate doses of ciprofloxacin and vancomycin for septic patients with acute renal failure (ARF) treated by continuous arteriovenous and venovenous haemodialysis, (CAVHD/CWHD), we performed pharmacokinetic studies in patients receiving these antibiotics. All patients were treated by CAVHD/CWHD using Hospal AN69S 0.43 m2 filters and Fresenius 1.5% peritoneal dialysis fluid at dialysate flow rates (Qd) of 1 and 2 1/h. Patients received ciprofloxacin 200 mg i.v. 12-hourly (n =6) or 8-hourly (n =5); vancomycin 1 g i.v. was administered to 10 patients approximately every 48 h to maintain therapeutic plasma levels. For ciprofloxacin, volume of distribution (Vdarea) was 136.5±9.81, terminal elimination half-life (t1/2) 6.4±0.8 h, and total body clearance (TBC) 264.3±22.9 ml/min (mean±SEM). Mean sieving coefficient (S/C) was 0.76±0.05 and filter clearances at Qd 1 and 21/h were 16.2±1.9 and 19.9± 1.1 ml/min respectively. For vancomycin, Vdarea was 60.7±5.11, t1/2 24.7±2.6h and TBC 31.0± 4.6 ml/min. Mean S/C was 0.66±0.08 and filter clearances at Qd 1 and 21002F;h 12.1±2.0 and 16.6± 2.0 ml/min. These data suggest that patients with ARF treated by CAVHD/CWHD should be given ciprofloxacin 200 mg i.v. 8–12-hourly and vancomycin every 48 h.

Keywords: acute renal failure; continuous arterioven


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
R. S. Malone, D. N. Fish, E. Abraham, and I. Teitelbaum
Pharmacokinetics of Levofloxacin and Ciprofloxacin during Continuous Renal Replacement Therapy in Critically Ill Patients
Antimicrob. Agents Chemother., October 1, 2001; 45(10): 2949 - 2954.
[Abstract] [Full Text]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.